

April 28, 2021

Stayble strengthens its team by recruiting VP CMC and Regulatory Affairs

Stayble Therapeutics announced today that the company is strengthening its team by recruiting Dr. Sara Richardson in the newly created role VP CMC and Regulatory Affairs. Dr. Richardson will primarily work with the company's continued clinical development, particularly with manufacturing issues (CMC), regulatory issues and government interactions.

"Dr. Richardson will play a key role in the company, especially in the ongoing clinical development of our drug candidate STA363. I am very happy to welcome Dr. Richardson to the team with her expertise and experience being very valuable for our continued development plans", says Andreas Gerward, CEO of Stayble."

Dr. Richardson has a doctorate in analytical chemistry from Lund University and has had a long career at AstraZeneca where she worked with research, clinical development and leadership. Most recently, with responsibility for manufacturing issues (CMC) regarding development of drug candidates in clinical phase. The role also included responsibility for strategy development, outsourcing of clinical manufacturing and regulatory applications to the European Medicines Agency EMA and US FDA. Previous roles include group leader with responsibility for formulation and analysis development in clinical phases as well as various research roles in drug development projects from Phase 1 to Phase 3.

Dr. Richardson will join Stayble on July 1, 2021.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se, | +46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se. More information on www.staybletherapeutics.com.